Literature DB >> 16720979

Neutralizing antibody patterns and viral escape in HIV-1 non-B subtype chronically infected treatment-naive individuals.

Halonna R Kelly1, Mateusz Urbanski, Sherri Burda, Ping Zhong, Frank Konings, Joseph Nanfack, Marcel Tongo, Thompson Kinge, Jacqueline Achkar, Phillipe Nyambi.   

Abstract

Here we studied the patterns of generation of neutralizing antibodies (NAbs) and virus escape during non-B subtype HIV-1 chronic infection among asymptomatic patients, and established whether a correlation exists between the generation of NAbs and the kinetics of CD4 T-cell decline. Therefore, sequential viruses and plasma obtained at 6 months to one year intervals over a three years period from ten HIV-1 group M subtype A, CRF02_AG, G, and H infected treatment-naïve individuals were tested in neutralization assays. Overall, NAbs were present in all ten individuals, and had the capacity to neutralize autologous virus obtained six months earlier. Eight of the ten subjects showed an increasing capacity to neutralize early viruses and a low capacity to neutralize contemporaneous and later time-point viruses. The neutralizing activities within these individuals resulted in emergence of neutralization resistant viruses, and with the subsequent generation of more NAbs to the emerging resistant viruses. In the remaining two individuals, the capacity to neutralize early, contemporaneous, and later time-point viruses remained conserved. While the kinetics of CD4 T-cell decline varied among all ten individuals, there was no correlation with the capacity to generate NAbs in that, sequential plasmas from individuals with moderately or rapidly declining CD4 T-cells were capable of neutralizing early sequential viruses. We conclude from this study that in non-B subtype chronically infected asymptomatic patients with moderately and rapidly declining CD4 T-cells, potent NAbs are readily generated as the virus evolves to escape the effect of these antibodies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16720979

Source DB:  PubMed          Journal:  Hum Antibodies        ISSN: 1093-2607


  6 in total

1.  Neutralizing and other antiviral antibodies in HIV-1 infection and vaccination.

Authors:  David C Montefiori; Lynn Morris; Guido Ferrari; John R Mascola
Journal:  Curr Opin HIV AIDS       Date:  2007-05       Impact factor: 4.283

2.  Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.

Authors:  M Anthony Moody; Feng Gao; Thaddeus C Gurley; Joshua D Amos; Amit Kumar; Bhavna Hora; Dawn J Marshall; John F Whitesides; Shi-Mao Xia; Robert Parks; Krissey E Lloyd; Kwan-Ki Hwang; Xiaozhi Lu; Mattia Bonsignori; Andrés Finzi; Nathan A Vandergrift; S Munir Alam; Guido Ferrari; Xiaoying Shen; Georgia D Tomaras; Gift Kamanga; Myron S Cohen; Noel E Sam; Saidi Kapiga; Elin S Gray; Nancy L Tumba; Lynn Morris; Susan Zolla-Pazner; Miroslaw K Gorny; John R Mascola; Beatrice H Hahn; George M Shaw; Joseph G Sodroski; Hua-Xin Liao; David C Montefiori; Peter T Hraber; Bette T Korber; Barton F Haynes
Journal:  Cell Host Microbe       Date:  2015-09-09       Impact factor: 21.023

3.  In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies.

Authors:  Marlén M I Aasa-Chapman; Kelly M Cheney; Stéphane Hué; Anna Forsman; Stephen O'Farrell; Pierre Pellegrino; Ian Williams; Áine McKnight
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

4.  Neutralization patterns and evolution of sequential HIV type 1 envelope sequences in HIV type 1 subtype B-infected drug-naive individuals.

Authors:  Phillipe Nyambi; Sherri Burda; Mateusz Urbanski; Leo Heyndrickx; Wouter Janssens; Guido Vanham; Arthur Nadas
Journal:  AIDS Res Hum Retroviruses       Date:  2008-12       Impact factor: 2.205

5.  Extensive complement-dependent enhancement of HIV-1 by autologous non-neutralising antibodies at early stages of infection.

Authors:  Suzanne Willey; Marlén M I Aasa-Chapman; Stephen O'Farrell; Pierre Pellegrino; Ian Williams; Robin A Weiss; Stuart J D Neil
Journal:  Retrovirology       Date:  2011-03-14       Impact factor: 4.602

Review 6.  Hepatitis C virus vaccine design: focus on the humoral immune response.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  J Biomed Sci       Date:  2020-07-06       Impact factor: 8.410

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.